CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.

Ingrid Boere,Ignace Vergote,Rob Hanssen,Mathilde Jalving,Christine Gennigens,Petronella Ottevanger,Yes J van de Wouw,Cristianne J F Rijcken,Ron H J Mathijssen,Jonathan Ledermann

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society（2023）

引用 1|浏览18

暂无评分

摘要

Treatment with CPC634 was feasible, but without apparent clinical activity in patients with recurrent platinum-resistant ovarian cancer. Side effects were mainly gastrointestinal in 24 (96%) patients, including nausea, vomiting, and decreased appetite, fatigue, anemia, and dyspnea.

查看译文

关键词

Cystadenocarcinoma, Serous,Ovarian Cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要